Therapy Insight: How changes in renal function with increasing age affect cardiovascular drug prescribing

Nature Clinical Practice Cardiovascular Medicine

Volumn 3, Issue 2, 2006, Pages 102-109

  Wyatt, Christina M ^a   Kim, Michael C ^a   Winston, Jonathan A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Dosing; Drug prescribing; Drug therapy; Elderly; Renal function

Indexed keywords

ABCIXIMAB; ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; FIBRINOGEN RECEPTOR ANTAGONIST; GEMFIBROZIL; HEPARIN; IBUTILIDE; LOOP DIURETIC AGENT; NADOLOL; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; PROCAINAMIDE; SOTALOL; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; WARFARIN;

ACUTE CORONARY SYNDROME; AGING; ANTICHOLINERGIC EFFECT; BLEEDING; BRADYCARDIA; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; CONSTIPATION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; GEOGRAPHIC DISTRIBUTION; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPONATREMIA; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; KIDNEY FUNCTION; METABOLIC DISORDER; POPULATION DISTRIBUTION; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TORSADE DES POINTES; UNITED STATES;

AGED; AGING; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; RENAL INSUFFICIENCY, CHRONIC;

EID: 32144433909     PISSN: 17434297     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpcardio0433     Document Type: Review

References (52)

1. US Census Bureau (online 18 March 2004) US interim projections by age, sex, race, and hispanic origin. [http://www.census.gov/ipc/www/ usinterimproj/] (accessed 1 August 2005)
2. Rowe JW et al. (1976) The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol 31: 155-163
3. McCullough PA et al. (2000) Risks associated with renal dysfunction in patients in the coronary care unit. J Am Coll Cardiol 36: 679-684
4. Shlipak MG et al. (2002) Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 137: 555-562
5. Al Suwaidi J et al. (2002) Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 106: 974-980
6. Wright RS et al. (2002) Acute myocardial infarction and renal dysfunction: A high risk combination. Ann Intern Med 137: 563-570
7. Shlipak MG et al. (2004) Renal function, digoxin therapy, and heart failure outcomes: Evidence from the digoxin intervention group trial. J Am Soc Nephrol 15: 2195-2203
8. Go AS et al. (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305
9. Weiner DE et al. (2004) Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: A pooled analysis of community-based studies. J Am Soc Nephrol 15: 1307-1315
10. Anavekar NS et al. (2004). Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351: 1285-1295
11. Tonelli M et al. (2001) Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis 37: 484-489
12. McCullough PA et al. (2002) Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J 144: 226-232
13. Coresh J et al. (2003) Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41: 1-12
14. Coresh J et al. (2005) Chronic kidney disease awareness, prevalence, and trends among US adults, 1999 to 2000. J Am Soc Nephrol 16: 180-188
15. Corsonello A et al. (2005) Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients. Arch Intern Med 165: 790-795
16. National Kidney Foundation. Kidney disease outcomes quality initiative. Clinical practice guidelines [http://www.kidney.org/professionals/kdoqi/ guidelines.cfm] (accessed 1 August 2005)
17. Cockcroft DW and Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41
18. Levey AS et al. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-470
19. Froissart M et al. (2005) Predictive performance of the MDRD and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol 16: 763-773
20. Verhave JC et al. (2004) Drawbacks of the use of indirect estimates of renal function to evaluate the effect of risk factors on renal function. J Am Soc Nephrol 15: 1316-1322
21. Bostom AG et al. (2002) Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol 13: 2140-2144
22. Baracskay D et al. (1997) Geriatric renal function: Estimating glomerular filtration in an ambulatory elderly population. Clin Nephrol 47: 222-228
23. Coresh J et al. (2002) Estimating the prevalence of low glomerular filtration rate requires attention to the creatinine assay calibration. J Am Soc Nephrol 13: 2811-2812
24. Coresh J et al. (2002) Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate the glomerular filtration rate. Am J Kidney Dis 39: 920-929
25. Fick DM et al. (2003) Updating the Beers criteria for potentially inappropriate medication use in older adults: Results of a US consensus panel of experts. Arch Intern Med 163: 2716-2724
26. Chobanian AV et al.(2003) Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42: 1206-1252
27. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) (1997) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 857-1863
28. Brenner BM et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869
29. Lewis EJ et al. (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860
30. Shlipak MG (2003) Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med 138: 917-924
31. Bakris GL and Weir M (2000) Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern? Arch Intern Med 160: 685-693
32. Ljungman S et al. (1992) Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol 70: 479-487
33. Tamirisa KP et al. (2004) Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J 148: 971-978
34. Dussol B et al. (2005) A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension. Nephrol Dial Transplant 20: 349-353
35. Oparil S et al. (1999) Fenoldopam: A new parenteral antihypertensive: consensus roundtable on the management of perioperative hypertension and hypertensive crises. Am J Hypertens 12: 653-664
36. Devlin JW et al. (2004) Fenoldopam versus nitroprusside for the treatment of hypertensive emergency. Ann Pharmacother 38: 755-759
37. Reddan D et al. (2003) Anticoagulation in acute cardiac care in patients with chronic kidney disease. Am Heart J 145: 586-594
38. Becker RC et al. (2002) Influence of patient characteristics and renal function on factor Xa inhibition, pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 143: 753-759
39. Spinler SA et al. (2003) Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: Analysis from the ESSENCE and TIMI 11B studies. Am Heart J 146: 33-41
40. Kruse MW and Lee JJ (2004) Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment. Am Heart J 148: 582-589
41. Oster JR et al. (1995) Heparin-induced aldosterone suppression and hyperkalemia. Am J Med 98: 575-586
42. Smith NL (1999) Temporal trends in the use of anticoagulants among older adults with atrial fibrillation. Arch Intern Med 159: 1574-1578
43. Siguret V et al. (2005) Initiation of warfarin therapy in elderly medical inpatients: A safe and accurate regimen. Am J Med 118: 137-142
44. Ansell J et al. (2004) The pharmacology and management of the vitamin K antagonists: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 (Suppl 3): 204S-233S
45. Buresly K et al. (2005) Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med 165: 784-789
46. Baigent C et al. (2005) First United Kingdom Heart and Renal Protection (UK-HARP-1) study: Biochemical efficacy and safety of simvastatin and safety of low dose aspirin in chronic kidney disease. Am J Kidney Dis 45: 473-484
47. Reddan DN et al. (2003) Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial). Am J Cardiol 91: 17-21
48. Freeman RV et al. (2003) Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 41: 718-724
49. Best PJ et al. (2003) Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. Am Heart J 146: 213-214
50. Bianchi S et al. (2003) A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41: 565-570
51. Tonelli M et al. (2003) Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 14: 1605-1613
52. Sackner-Bernstein JD et al. (2005) Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111: 1487-1491